PHILADELPHIA , Sept. 15, 2025 /PRNewswire/ --Â Berger Montague, a national securities litigation law firm, advises shareholders of Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) about an investigation into Hims & Hers' Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Novo Nordisk A/S's termination of its partnership with Hims & Hers. ...

Core Insights - The article compares two companies, Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS), to determine which is a better option for value investors [1] Valuation Metrics - Omnicell has a Zacks Rank of 2 (Buy), indicating stronger earnings estimate revision activity compared to Hims & Hers, which has a Zacks Rank of 3 (Hold) [3] - Omnicell's forward P/E ratio is 21.22, while Hims & Hers has a significantly higher forward P/E of 92.79 [5] - Omnicell's PEG ratio is 3.41, compared to Hims & Hers' PEG ratio of 3.75, suggesting that Omnicell may be more reasonably valued in relation to its expected earnings growth [5] - Omnicell's P/B ratio is 1.16, indicating a more favorable comparison of market value to book value, while Hims & Hers has a P/B ratio of 22.27 [6] - Based on these valuation metrics, Omnicell holds a Value grade of A, whereas Hims & Hers has a Value grade of D [6] Conclusion - Overall, Omnicell demonstrates stronger estimate revision activity and more attractive valuation metrics than Hims & Hers, making it the superior option for value investors at this time [7]

FDA此次表态前，美国总统唐纳德·特朗普已于本周二签署一份总统备忘录，敦促其政府加强对面向消 费者(DTC)的药品广告法规的执法力度，以确保广告内容的透明度与准确性。 同日，FDA宣布将向制药公司发出约100份终止令和数千封警告信，提醒企业遵守面向消费者的药品广 告规则。 智通财经APP获悉，美国食品药品监督管理局(FDA)局长马丁·马卡里于上周五表示，Hims & Hers公司 (HIMS.US)在超级碗期间投放的广告违反了联邦法律。该广告仅强调了减肥药物的益处，却未提及任何 副作用。 马卡里在《美国医学会杂志》(JAMA，由美国医学会出版的同行评审医学期刊)中指出，根据联邦法 律，处方药广告必须"公平平衡"地呈现药物的风险与益处。 他还特别提到FDA的执法力度已大幅减弱：在20世纪90年代末，FDA每年会发出数百封警告信，而2023 年全年仅发出1封，2024年至今则一封未发。 对此，Hims & Hers的一位发言人回应称，公司的"超级碗广告并未宣传任何一种特定疗法或解决方 案"。 该发言人在电子邮件声明中表示："相反，广告旨在通过展示肥胖问题的影响，以及民众难以获得能挽 救生命的全面减重医疗服务这一现 ...

Food and Drug Administration Commissioner Martin Makary stated on Friday that Hims & Hers Health Inc. HIMS broke federal law with its Super Bowl commercial promoting weight-loss drugs.Check out the current price of HIMS stock here. FDA Cites Federal Law BreachThe advertisement failed to adequately disclose the drugs' potential side effects, violating rules that require prescription medication ads to present a balanced view of benefits and risks, Reuters reported. Makary expressed this view in JAMA, a peer-r ...

Core Viewpoint - The U.S. Food and Drug Administration (FDA) has indicated that Hims & Hers' Super Bowl advertisement violated federal law by promoting the benefits of weight-loss drugs without proper disclaimers [1] Group 1 - The FDA Commissioner Martin Makary stated that the advertisement highlighted the advantages of weight-loss medications [1] - The advertisement's failure to comply with federal regulations raises concerns about the marketing practices of Hims & Hers [1]

Core Insights - Hims & Hers Health, Inc. (HIMS) has seen a stock increase of 64.1% over the past six months, outperforming the industry average of 23.8% and the S&P 500's gain of 20.8% [1][9] - The company has launched a new men's health category and reported strong second-quarter 2025 results, indicating growth in subscribers and online revenue [2][3] Financial Performance - Hims & Hers reported significant improvements in both top and bottom lines, with a notable increase in online revenue per average subscriber [3][10] - The company expects third-quarter 2025 revenues between $570 million and $590 million, reflecting a year-over-year increase of 42-47%, and full-year revenues between $2.3 billion and $2.4 billion, representing growth of 56-63% from 2024 levels [7][10] Market Position - Hims & Hers has outperformed competitors like Teladoc Health, Inc. and American Well Corporation, which saw stock declines of 8.5% and 14.5%, respectively, over the same period [6][9] - The company's forward 12-month price-to-sales (P/S) ratio is 4.4X, lower than the industry average of 6.1X but higher than its three-year median of 2.4X [16] Strategic Developments - Hims & Hers is expanding internationally, including the acquisition of ZAVA, which has 1.3 million active customers in Europe, and plans to enter Canada in 2026 [11][12] - The company has launched a men's health category in partnership with Marius Pharmaceuticals, introducing oral testosterone therapy to address a significant unmet need [13][14] Operational Momentum - The company has shown strong operational momentum with increased customer adoption of personalized treatment plans and higher engagement levels [10] - Management's confidence in reaffirming its full-year outlook indicates resilience in its business model and effective execution of growth strategies [10][20]

Group 1 - Hims & Hers Health Inc. (NYSE: HIMS) has experienced significant volatility in its stock price, particularly due to increased interest from retail investors [1] - The company operates in the telehealth sector, drug distribution, and provides GLP-1 medications, indicating a diversified business model [1] Group 2 - The article does not provide specific financial metrics or performance data related to Hims & Hers Health Inc. [1]

Core Viewpoint - Marius Pharmaceuticals has announced a collaboration with Hims & Hers to make KYZATREX®, an FDA-approved oral testosterone replacement therapy, available to patients through the Hims & Hers platform, marking a significant step in improving access to testosterone therapy for men with low testosterone levels [1][4]. Company Overview - Marius Pharmaceuticals focuses on therapies for hypogonadism or testosterone deficiency, aiming to improve metabolic health and reduce unnecessary healthcare costs [5]. - Hims & Hers is a leading digital health platform that aims to empower individuals with access to high-quality care and education, enhancing the delivery of men's health solutions [4]. Product Details - KYZATREX® is an oral formulation of testosterone undecanoate, primarily absorbed via the lymphatic system, which minimizes liver toxicity [6]. - Clinical studies have shown that KYZATREX is up to 96% effective in restoring testosterone levels, with 88% of participants achieving normal testosterone levels by Day 90 [3][8]. - The product is indicated for adult males with low or absent endogenous testosterone levels due to specific medical conditions [10]. Market Implications - The collaboration aims to address the underdiagnosed condition of testosterone deficiency, which affects men's health and quality of life, by leveraging Hims & Hers' digital platform and patient education resources [2][4]. - This partnership is expected to break down barriers to care, making innovative treatments more accessible and personalized for patients [4].

TRENDING: See Nvidia's Growing Appetite For Startup Investments Hims stock popped Wednesday after the telemedicine giant announced its long-awaited foray into offering testosterone replacement therapy. The announcement was highly anticipated given Hims & Hers Health (HIMS) has long discussed its plan to launch a testosterone replacement therapy, or TRT. There will be four options, offered in partnership with privately held Marius Pharmaceuticals. Pricing has yet to be outlined, but will likely run in the ra ...

周三，Hims&Hers Health(HIMS.US)股价走高，截至发稿，该股涨超7%，报51.39美元。消息面上，该 公司宣布，2026年将通过与睾酮疗法创新领军企业Marius Pharmaceuticals合作，在其平台上独家推出一 款口服睾酮药物KYZATREX。这款药物已经获得美国食品药品监督管理局批准，无需注射，使用更加 便捷。据临床数据，KYZATREX可使高达96%的男性恢复正常睾酮水平，同时将"游离睾酮"翻倍提升。 游离睾酮被认为与精力、驱动力和身体表现密切相关，而该药物在提升疗效的同时保持了较低的不良反 应率。 ...